Katy Beckermann: Exciting update from Dr. Mike Atkins on the novel checkpoint inhibitor LAG3 and its potential role in kidney cancer treatment
Katy Beckermann, Assistant Professor at Vanderbilt University Medical Center, shared a post by GU Oncology Now on X/Twitter:
“Exciting update from Dr. Mike Atkins on the novel checkpoint inhibitor LAG3 and its potential role in kidney cancer treatment. Stay tuned for the latest developments in immunotherapy!”
Quoting GU Oncology Now’s post:
“Don’t miss out on the conversation between Katy Beckermann of Vanderbilt-Ingram Cancer Center and Michael Atkins, MD, of Georgetown Lombardi, about the rationale behind targeting LAG-3 as a novel checkpoint inhibitor in Kidney Cancer.
Source: Katy Beckermann/X and GU Oncology Now/X
About OncoDaily
OncoDaily was founded in 2023. It is a US-based oncology media platform, which features the latest news, insights, and patient stories from the world of oncology. Within a short period of time it became one of the leading oncology media platforms globally.
OncoDaily gathers content from various sources, including social media posts from renowned oncologists from all over the world, news from oncology societies and cancer centers, patient and survivor stories, and career-related information for professionals.
The mission of OncoDaily is to empower patients, survivors, and professionals with the knowledge and inspiration they need to fight cancer. The motto of OncoDaily is “Cancer doesn’t take a day off – neither do we“.